Singapore, March. 20, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that the company received the “Best Contract Development and Manufacturing Organization Award” and the “Bioprocessing Excellence in Greater China Region Award” at the 2023 APAC Bioprocessing Excellence Awards (ABEA) ceremony. This marks the sixth time that the company has received an award from the organizer IMAPAC, a professional consulting firm in the biopharmaceutical industry.
In 2022, WuXi Biologics supported its global clients to obtain 123 Investigational New Drug (INDs) approvals, including a novel RNA product. The company’s global manufacturing network is currently supporting 17 commercial biologics and vaccines, with the capacity to support more commercial projects across its 14 drug substance (DS) manufacturing facilities and 9 drug product (DP) fill sites. WuXi Biologics’ global quality system has passed a total of 27 regulatory inspections – from the U.S. FDA, EMA, PMDA, NMPA, MFDS, HSA, HPRA, Health Canada, ANVISA and the WHO – and multiple commercial licenses have been granted to its manufacturing clients.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are honored to be recognized as the ‘Best CDMO’ in the global biopharmaceutical industry. This award – along with the ‘Bioprocessing Excellence in Greater China Region’ award – speaks to the efforts made by each of our employees and the satisfaction of our partners. The recognition will further inspire us to enable global partners by accelerating and transforming the discovery, development and manufacturing of innovative biologics for the benefit of patients worldwide.”
Recognizing the outstanding achievements of top biomanufacturing companies, the ABEA applauds extraordinary leaders and trend-setters of today and inspires innovators of tomorrow. Every year, the ABEA shortlists 5-7 nominees under each award category, and the final winners are determined by voting results from the public or bioprocessing community.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com